Phase I, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Tremelimumab in Combination With Gefitinib in EGFR Mutant NSCLC Patients

Trial Profile

Phase I, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Tremelimumab in Combination With Gefitinib in EGFR Mutant NSCLC Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Gefitinib (Primary) ; Tremelimumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms GEFTREM
  • Most Recent Events

    • 11 Oct 2016 Results (n=26) presented at the 41st European Society for Medical Oncology Congress
    • 08 Jun 2016 Status changed from recruiting to completed.
    • 05 Feb 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top